Valemetostat
Other/Multi
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): A multicentre, open-label, single-arm, phase 2 study
Zinzani PL, Izutsu K, Mehta-Shah N, et al.
Lancet Oncol. 2024;25(12):1602-1613. doi: 10.1016/S1470-2045(24)00503-5
Valemetostat
Other/Multi
Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: A first-in-human, multicentre, open-label, single-arm, phase 1 study
Maruyama D, Jacobsen E, Porcu P, et al.
Lancet Oncol. 2024;25(12):1589-1601. doi: 10.1016/S1470-2045(24)00502-3
Edoxaban
Cardiovascular - AF
Bioprosthetic valve positions in patients with atrial fibrillation- insights from the BPV-AF registry
Obayashi Y, Miyake M, Takegami M, et al.
Circ Rep. 2024;6(11):521-528. doi: 10.1253/circrep.CR-24-0110.
T-DXd
Gastric Cancer
Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study)
Kawakami H, Nakanishi K, Makiyama A, et al.
Gastric Cancer. 2025;28(1):51-61. doi: 10.1007/s10120-024-01555-w
HER3-DXd
Lung Cancer
HER3 is widely expressed across diverse subtypes of NSCLC in a retrospective analysis of archived tissue samples
Soo RA, Clinthorne G, Santhanagopal A, et al.
Future Oncol. 2024;20(37):2961-2970. doi: 10.1080/14796694.2024.2398983. Epub 2024.
T-DXd
Breast Cancer
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: A phase 3b/4 trial
Harbeck N, Ciruelos E, Jerusalem G, et al.
Nat Med. 2024;30(12):3780. doi: 10.1038/s41591-024-03349-0.
Dato-DXd
Breast Cancer
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: Primary results from TROPION-Breast01
Bardia A, Jhaveri K, Im S-A, et al.
J Clin Oncol. 2025;43(3):285-296. doi: 10.1200/JCO.24.00920.
Edoxaban
Cardiovascular - AF
Cardiovascular - VTE
Exposure matching-based pediatric dose selection for drugs with renal excretion - lessons learned from pediatric development of direct oral anticoagulants
Zou P, Leil TA
Clin Pharmacol Ther. 2024;116(5):1174-1187. doi: 10.1002/cpt.3396.
T-DXd
Breast Cancer
Global study on the accuracy of human epidermal growth factor receptor 2-low diagnosis in breast cancer
Rüschoff J, Penner A, Ellis IO, et al.
Arch Pathol Lab Med. 2024. doi: 10.5858/arpa.2024-0052-OA. Epub ahead of print.
T-DXd
Colorectal Cancer
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): Primary results from a multicentre, randomised, phase 2 trial
Raghav K, Siena S, Takashima A, et al.